Black Diamond Therapeutics Inc (BDTX) Stock Price, Quote & News

Company Profile

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also develo...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 252 0848

Website: www.blackdiamondtherapeutics.com

Address:

One Main Street, 14th Floor, Cambridge, United States

billblank Oct. 3 at 4:22 PM

$BDTX i saw that spike :)

0 · Reply

HouseOfTheDragons Oct. 3 at 2:35 AM

Looks like volume & momentum could be shifting in to ASTC! Tiny float getting a lot of attention and could explode upwards on volume. Watchers on ASTC are growing very fast and it could be the potential top runner for this week! Starting its 300% run - keep it on watch! Also watching for breakout: $BDRX $BDTX $BE $BGLC ---

0 · Reply

Invest2live Oct. 2 at 3:58 AM

$NCNA 65% already; checkout $CUE and $BDTX

0 · Reply

Tfunk81 Oct. 1 at 11:38 PM

$BDTX keep this running

0 · Reply

REKEV1 Sep. 30 at 3:37 PM

$BDTX

0 · Reply

StockRegulationBot Sep. 30 at 2:28 PM

$BDTX

0 · Reply

StockConsultant Sep. 30 at 12:28 PM

$BDTX solid breakout

0 · Reply

highnihilism Sep. 30 at 10:36 AM

$CIM Chimera Investment: 92 trades, $65K vs $59K avg (1.10x). $28K calls / $37K puts. $ARES Ares Management: 118 trades, $774K vs $1.2M avg (0.65x). $28K calls / $746K puts. $BDTX Black Diamond Therapeutics: 85 trades, $28K vs $8K avg (3.38x !!). $28K calls / $0.3K puts. $NMAX Newsmax: 424 trades, $92K vs $353K avg (0.26x !!). $28K calls / $64K puts.

0 · Reply

JW_Stocks Sep. 30 at 3:36 AM

$BDTX Clean break

0 · Reply

RunnerSignals Sep. 29 at 8:40 PM

Market Warriors Rally Back $XNET $BDTX $ABSI $CYTK $COCO flipped the script today with big intraday comebacks. Who's watching for round 2 tomorrow?

0 · Reply

Black Diamond Therapeutics: A Potential First-Line In NSCLC Trading At Cash

Aug 7, 2025, 7:30 AM EDT - 2 months ago

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 10, 2025, 6:38 AM EDT - 4 months ago

Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant Upside

May 29, 2025, 8:00 AM EDT - 4 months ago

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

May 12, 2025, 4:05 PM EDT - 5 months ago

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 31, 2025, 8:00 AM EDT - 6 months ago

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Mar 25, 2025, 12:58 AM EDT - 6 months ago

Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier

Mar 19, 2025, 7:00 AM EDT - 7 months ago

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

Mar 13, 2025, 3:47 PM EDT - 7 months ago

Black Diamond Therapeutics: In Decline, But Why?

Mar 6, 2025, 4:01 PM EST - 7 months ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Dec 30, 2024, 3:07 PM EST - 9 months ago

Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts

Nov 5, 2024, 8:00 AM EST - 11 months ago

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 8, 2024, 3:24 PM EDT - 1 year ago

Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data

Oct 7, 2024, 4:01 PM EDT - 1 year ago

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Sep 23, 2024, 7:00 AM EDT - 1 year ago

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

Sep 22, 2024, 10:00 AM EDT - 1 year ago

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Sep 14, 2024, 3:30 AM EDT - 1 year ago

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 27, 2024, 10:38 AM EDT - 1 year ago

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Jun 1, 2024, 10:00 AM EDT - 1 year ago

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 9, 2024, 7:30 AM EDT - 1 year ago

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Announces Changes to Board of Directors

Apr 7, 2024, 6:00 PM EDT - 1 year ago

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

Mar 24, 2024, 11:25 PM EDT - 1 year ago

Rise Of The Rest, Look Past Mega Caps, And Invest Elsewhere

AAPL AER AMZN BA DFH DHI GE

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 5, 2024, 4:30 PM EST - 1 year ago

Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024

Feb 28, 2024, 8:00 AM EST - 1 year ago

Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 12, 2024, 5:21 PM EST - 1 year ago

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Jan 4, 2024, 8:00 AM EST - 1 year ago

Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones

Dec 13, 2023, 7:00 AM EST - 1 year ago

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

Nov 6, 2023, 7:45 AM EST - 2 years ago

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 14, 2023, 12:30 PM EDT - 2 years ago

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Oct 12, 2023, 8:31 AM EDT - 2 years ago

Black Diamond's BDTX-1535: A Brainy Bet In Cancer Therapy

Oct 4, 2023, 12:14 PM EDT - 2 years ago

Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 18, 2023, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces CEO Transition

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer

Aug 11, 2023, 7:30 AM EDT - 2 years ago

Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 8:53 AM EDT - 2 years ago

Black Diamond Therapeutics: MasterKey Approach Validated With Lung Cancer Update

Jun 29, 2023, 8:57 PM EDT - 2 years ago

Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock

Jun 28, 2023, 6:51 PM EDT - 2 years ago

Black Diamond: On Right Track For Possible Accelerated Approval Pathway

Jun 28, 2023, 4:23 PM EDT - 2 years ago

Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock

Jun 27, 2023, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

Jun 13, 2023, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference

May 9, 2023, 7:30 AM EDT - 2 years ago

Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days

Apr 17, 2023, 4:01 PM EDT - 2 years ago

Black Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual Meeting

Mar 9, 2023, 7:30 AM EST - 2 years ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Feb 27, 2023, 8:00 AM EST - 2 years ago

Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

billblank Oct. 3 at 4:22 PM

$BDTX i saw that spike :)

0 · Reply

HouseOfTheDragons Oct. 3 at 2:35 AM

0 · Reply

Invest2live Oct. 2 at 3:58 AM

$NCNA 65% already; checkout $CUE and $BDTX

0 · Reply

Tfunk81 Oct. 1 at 11:38 PM

$BDTX keep this running

0 · Reply

REKEV1 Sep. 30 at 3:37 PM

$BDTX

0 · Reply

StockRegulationBot Sep. 30 at 2:28 PM

$BDTX

0 · Reply

StockConsultant Sep. 30 at 12:28 PM

$BDTX solid breakout

0 · Reply

highnihilism Sep. 30 at 10:36 AM

0 · Reply

JW_Stocks Sep. 30 at 3:36 AM

$BDTX Clean break

0 · Reply

RunnerSignals Sep. 29 at 8:40 PM

Market Warriors Rally Back $XNET $BDTX $ABSI $CYTK $COCO flipped the script today with big intraday comebacks. Who's watching for round 2 tomorrow?

0 · Reply

REKEV1 Sep. 29 at 6:25 PM

$BDTX

0 · Reply

100K2022 Sep. 29 at 6:15 PM

$BDTX is there news?

1 · Reply

waugusti Sep. 29 at 1:58 PM

$BDTX the long march to the summit begins now.

0 · Reply

StockRegulationBot Sep. 29 at 1:57 PM

$BDTX Hurry up and take it to $10. Especially right before the next earnings come out.

1 · Reply

Nb713 Sep. 29 at 1:51 PM

$BDTX

0 · Reply

ZacksResearch Sep. 25 at 5:05 PM

$BDTX up 52.3% YTD — can it keep climbing? 🚀 Silevertinib’s potential to target over 50 oncogenic mutations in EGFRm NSCLC and GBM sets it apart. BDTX's shares are valued at 1.40x book value compared to the biotech industry’s 3.20x. With a Zacks Rank of #1, it’s on the radar. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2757249/will-bdtxs-egfr-inhibitor-bring-a-paradigm-shift-in-nsclc-treatment?cid=sm-stocktwits-2-2757249-body-14168&ADID=SYND_STOCKTWITS_TWEET_2_2757249_BODY_14168

1 · Reply

ZacksResearch Sep. 25 at 4:05 PM

Game-changer for $BDTX in NSCLC? 🚀 Silevertinib is being positioned to challenge Tagrisso with broad EGFR mutation coverage, and pivotal trial results are expected in late 2025. Discover the potential impact here 👉 https://www.zacks.com/stock/news/2757249/will-bdtxs-egfr-inhibitor-bring-a-paradigm-shift-in-nsclc-treatment?cid=sm-stocktwits-2-2757249-teaser-14167&ADID=SYND_STOCKTWITS_TWEET_2_2757249_TEASER_14167

0 · Reply

ZacksResearch Sep. 23 at 2:32 PM

$BDTX vs. $CGEM — Why BDTX is the better pick! 🚀 🔍 BDTX's silevertinib is a promising EGFR inhibitor, targeting over 50 oncogenic mutations with strong potency. Plus, it's showing progress in both newly diagnosed and recurrent NSCLC cases. 📈 BDTX boasts a Zacks Rank #2 (Buy) and a 59.8% YTD surge in shares, compared to CGEM's 48.4% loss. Discover the full breakdown here 👉 https://www.zacks.com/stock/news/2755735/bdtx-vs-cullinan-therapeutic-which-egfr-challenger-is-the-better-buy?cid=sm-stocktwits-2-2755735-body-13669&ADID=SYND_STOCKTWITS_TWEET_2_2755735_BODY_13669

0 · Reply

ZacksResearch Sep. 23 at 1:32 PM

$BDTX vs. $CGEM — which EGFR play wins? Both are chasing next-gen EGFR inhibitors, but silevertinib’s potential plus valuation edge lean the scale toward BDTX. Full breakdown here 👉 https://www.zacks.com/stock/news/2755735/bdtx-vs-cullinan-therapeutic-which-egfr-challenger-is-the-better-buy?cid=sm-stocktwits-2-2755735-teaser-13635&ADID=SYND_STOCKTWITS_TWEET_2_2755735_TEASER_13635

0 · Reply

Doozio Sep. 22 at 11:45 PM

$BDTX let’s bang bro. 🐒🍌🧠⏰♾️

0 · Reply

REKEV1 Sep. 22 at 8:27 PM

$BDTX only one direktion.....north!!!

0 · Reply

REKEV1 Sep. 22 at 7:26 PM

$BDTX

0 · Reply

Market Cap	212.37M
Revenue (ttm)	0.00
Net Income (ttm)	-69.68M
EPS (ttm)	N/A
PE Ratio	16.17
Forward PE	11.14
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	884,000
Avg Vol	925,792
Day's Range	N/A - N/A
Shares Out	56.94M
Stochastic %K	99%
Beta	3.07
Analysts	Strong Sell
Price Target	$9.80